An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Arcus Biosciences, Inc. (NYSE:RCUS) announced it will report its financial results and corporate update for Q3 2021 on November 8, 2021, after market close. The company focuses on developing innovative molecules and combination therapies for cancer treatment, working on five investigational medicines targeting pathways like TIGIT and PD-1. Founded in 2015, Arcus aims to expedite the development of first or best-in-class cancer therapies through collaboration with industry partners, patients, and physicians.
Positive
None.
Negative
None.
HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecule and combination medicines for people with cancer, today announced that the company will report its financial results and a corporate update for the third quarter ended September 30, 2021 after the market closes on Monday, November 8, 2021.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of five investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, CD73 and the adenosine axis. For more information about Arcus Biosciences clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
